Compositions and methods for immunooncology
US-2024417722-A1 · Dec 19, 2024 · US
Gammadelta T cell expansion procedure
US10557117B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10557117-B2 |
| Application number | US-201515532921-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 4, 2015 |
| Priority date | Dec 5, 2014 |
| Publication date | Feb 11, 2020 |
| Grant date | Feb 11, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A method for expanding a population of γδ T-cells is provided in which isolated activated Peripheral Blood Mononuclear Cells (PBMCs) are cultured in a medium comprising transforming growth factor beta (TGF-β) under conditions in which the production of effector γδ T-cells having therapeutic activity against malignant disease is favored. The use of TGF-β in the production of effector cells in particular Vγ9Vδ2 T-cells is also described and claimed.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for expanding a population of effector γδ T-cells, said method comprising culturing isolated Peripheral Blood Mononuclear Cells (PBMCs) in a medium comprising (i) transforming growth factor beta (TGF-β), (ii) interleukin-2 (IL-2), and (iii) an activator for Vγ9Vδ2 T-cells, wherein the medium is serum free. 2. The method of claim 1 wherein no additional cytokines are present in the medium. 3. The method of claim 1 wherein the activator is an aminobisphosphonate. 4. The method of claim 1 wherein the PBMCs are human PBMCs. 5. The method of claim 4 wherein the PBMCs are from a healthy human. 6. The method of claim 1 wherein CD19 B cells and/or αβ T-cells are removed from the expanded product. 7. The method of claim 3 wherein the aminobisphosphonate is zoledronic acid, alendronic acid, pamidronic acid, ibandronic acid, or a salt thereof. 8. The method of claim 7 wherein the aminobisphosphonate is zoledronic acid or a salt thereof. 9. The method of claim 4 wherein the effector γδ T-cells are human Vγ9Vδ2 T-cells. 10. The method of claim 4 wherein the PBMCs are from a human patient. 11. The method of claim 2 wherein the activator is an aminobisphosphonate. 12. The method of claim 2 wherein the PBMCs are human PBMCs. 13. The method of claim 12 wherein the PBMCs are from a healthy human. 14. The method of claim 2 wherein CD19 B cells and/or αβ T-cells are removed from the expanded product. 15. The method of claim 11 wherein the aminobisphosphonate is zoledronic acid, alendronic acid, pamidronic acid, ibandronic acid, or a salt thereof. 16. The method of claim 15 wherein the aminobisphosphonate is zoledronic acid or a salt thereof.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
specific for leukemia · CPC title
Antineoplastic agents · CPC title
Organic phosphate, e.g. beta glycerophosphate · CPC title
from blood or immune system cells · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10557117B2 cover?
- A method for expanding a population of γδ T-cells is provided in which isolated activated Peripheral Blood Mononuclear Cells (PBMCs) are cultured in a medium comprising transforming growth factor beta (TGF-β) under conditions in which the production of effector γδ T-cells having therapeutic activity against malignant disease is favored. The use of TGF-β in the production of effector cells in pa…
- Who is the assignee on this patent?
- King S College London
- What technology area does this patent fall under?
- Primary CPC classification C12N5/0636. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Feb 11 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).